Timeline
SkinBioTherapeutics says FRP forensic report imminent
Solvonis to prioritise Phase 3 for lead asset
Health & Bio Today: GSK, AstraZeneca, Hemogenyx Pharmaceuticals, Genflow Biosciences
Hemogenyx Pharmaceuticals shares fall after £3m fundraising
Genflow Biosciences shares higher as 'tier-1' talks advance
Eden Research says results expected to be broadly in line with consensus
Health & Bio Today: GSK's efimosfermin wins FDA Breakthrough and EMA PRIME status, PureTech Health, Ondine Biomedical, AstraZeneca
Ondine study shows 39.5% cut in ICU pneumonia and is accepted for CACCN oral presentation
AstraZeneca wins US approval for once-weekly Saphnelo self-injection
GSK subsidiary TESARO has anticipatory breach claim dismissed by Delaware court
The Premarket Brief: ECR Minerals, Ondine Biomedical, 88 Energy, Pathos Communications, Beowulf Mining
PureTech posts positive Phase 1b LYT-200 data and will prioritise relapsed/refractory high‑risk MDS
Ondine Biomedical to showcase at World Congress on Infectious Diseases
Renalytix expands testing capacity 3.5x and submits CE technical file for kidneyintelX.dkd
hVIVO to run pivotal Phase III whooping cough human challenge trial for ILiAD
Avacta demonstrates AVA6103 outdelivers Enhertu and reveals dual‑payload in vivo data
CRISM Therapeutics shows 58% tumour reduction with Docetaxel-ChemoSeed
IXICO reports 23% H1 revenue rise as order book expands to £18.1m
CelLBxHealth partners with The Royal Marsden on 200‑patient CTC study
Genflow Biosciences secures fully funded LNP collaboration with Acuitas Therapeutics
Poolbeg Pharma says TOPICAL trial gets greenlight
Obsidian to go public via Galera reverse merger backed by $350m private placement
GSK completes acquisition of 35Pharma for $950m
hVIVO revenue slides, strategy pivot offsets market hit
hVIVO inks influenza human challenge trial with Traws Pharma
Ondine boosted by patient enrolment, revenues rise and factory upgrades begin
Genflow’s SIRT6 patent fence widens
OXB launches fast-track services to cut GMP timelines by up to nine months
Genflow says its gene therapy for dogs maintains safety and efficacy three months after dosing
Solvonis secures another US patent for PTSD programme
Trellus Health signs MSA with Gastro Health to deploy TrialSet
Avacta to raise c.£10m via equity placing
More in Healthcare
Genedrive's personalised medicine receives Parliament boost
A government minister named Genedrive's newborn hearing-loss test as a live example of personalised medicine during a House of Commons committee session.